The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer

• Published in: European journal of nuclear medicine and molecular imaging 2013-01, Vol.40 (1), p.52-60
• Main Authors: Nakamura, Keiichiro, Joja, Ikuo, Fukushima, Chikako, Haruma, Tomoko, Hayashi, Chiaki, Kusumoto, Tomoyuki, Seki, Noriko, Hongo, Atsushi, Hiramatsu, Yuji
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Cancer; Carcinoma - diagnostic imaging; Carcinoma - mortality; Carcinoma - surgery; Cardiology; Computed tomography; Diffusion coefficient; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Endometrial cancer; Endometrial Neoplasms - diagnostic imaging; Endometrial Neoplasms - mortality; Endometrial Neoplasms - surgery; Endometrium; Female; Follow-Up Studies; Humans; Imaging; Magnetic resonance imaging; Medical prognosis; Medicine; Medicine & Public Health; Metabolism; Middle Aged; Multimodal Imaging; Multivariate Analysis; NMR; Nuclear magnetic resonance; Nuclear Medicine; Oncology; Original Article; Orthopedics; Positron-Emission Tomography; Preoperative Period; Prognosis; Radiology; Recurrence; Survival; Tomography; Tomography, X-Ray Computed
• ISSN: 1619-7070; 1619-7089
• DOI: 10.1007/s00259-012-2240-7

Purpose The purpose of this study was to investigate the prognostic value of the minimum apparent diffusion coefficient (ADCmin) derived from diffusion-weighted MR imaging and of the maximum standardized uptake value (SUVmax) derived from PET/CT imaging of the primary tumour in patients with endometrial cancer. Methods SUVmax reflects the highest tumour metabolism rate and ADCmin reflects the highest cellularity, and both parameters have been used for tumour grading and prediction of prognosis. The correlations between prognosis and SUVmax and ADCmin of the primary tumour were determined in 131 patients with endometrial cancer. The patients were divided into groups based on ADCmin and SUVmax cut-off values to predict recurrence and survival, which were derived from receiver operating characteristic curves. Disease-free survival (DFS) and overall survival (OS) of the groups were analysed using the Kaplan-Meier method, and differences between survival curves were evaluated using the log-rank test. Results The median DFS and OS times of all patients were 19.2 and 20.5 months (follow-up periods 1–70 months for both DFS and OS), respectively. Patients with high SUVmax had significantly lower DFS ( P